Aquestive Therapeutics, Inc.: basic weighted-average shares

What this measure means

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

Exact concept: us-gaap:WeightedAverageNumberOfSharesOutstandingBasic. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.

Coverage of this history

Selected reporting periods run from 2020-01-01 to 2025-12-31. The SEC response was captured on 2026-09-20.

Reading these values

This selected numerical history matches Diluted weighted-average shares for the same reporting intervals and original units. The accounting definitions remain distinct. Equal values do not establish that the concepts are interchangeable or explain why they match; filing dates and accessions may differ. Compare the definitions and source filings before combining them.

Context from the filing

Aquestive Therapeutics' 2024 and 2025 statements display dollar losses in thousands, while the EPS and denominator rows explicitly use dollars per share and full shares. Options, restricted stock units, warrants and employee stock purchase plan shares are excluded as anti-dilutive during losses, so basic and diluted loss EPS are equal. The filing separately states that its 2022 prefunded warrants were fully exercised in 2022; they are not an outstanding prefunded-warrant balance to add to the 2024 or 2025 denominator. Read the source filing.

Selected filing history

Related financial histories

• Aquestive Therapeutics, Inc.: total assets
• Aquestive Therapeutics, Inc.: total liabilities
• Aquestive Therapeutics, Inc.: stockholders equity
• Aquestive Therapeutics, Inc.: cash and cash equivalents
• Aquestive Therapeutics, Inc.: net income or loss
• Aquestive Therapeutics, Inc.: operating cash flow
• Aquestive Therapeutics, Inc.: capital expenditure payments
• Aquestive Therapeutics, Inc.: contract revenue excluding tax
• Aquestive Therapeutics, Inc.: financing cash flow
• Aquestive Therapeutics, Inc.: investing cash flow
• Aquestive Therapeutics, Inc.: retained earnings or deficit
• Aquestive Therapeutics, Inc.: diluted weighted-average shares
• Aquestive Therapeutics, Inc.: basic earnings per share
• Aquestive Therapeutics, Inc.: diluted earnings per share
• Aquestive Therapeutics, Inc.: income tax expense or benefit
• Aquestive Therapeutics, Inc.: net property, plant and equipment
• Aquestive Therapeutics, Inc.: share-based compensation expense
• Aquestive Therapeutics, Inc.: operating income or loss
• Aquestive Therapeutics, Inc.: current assets
• Aquestive Therapeutics, Inc.: interest expense
• Aquestive Therapeutics, Inc.: current liabilities
• Aquestive Therapeutics, Inc.: current accounts payable
• Aquestive Therapeutics, Inc.: net finite-lived intangible assets
• Aquestive Therapeutics, Inc.: operating expenses
• Aquestive Therapeutics, Inc.: net inventory
• Aquestive Therapeutics, Inc.: selling, general and administrative expense
• Aquestive Therapeutics, Inc.: research and development expense

Inspect the source

Entity

Aquestive Therapeutics, Inc. / CIK 0001398733

Captured

2026-09-20T08:00:26.480Z

SEC response SHA-256

3bdc66938934696ecad7ea83dddb8c52ff6f8163caff400dc82a94f7e5e2ce7c

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

• Get an API key and run your first validation
• Connect the MCP server to your coding assistant
• Inspect the ALPHAC engine on GitHub
• Read the MCP server source and integration examples

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001398733.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))